Search

Your search keyword '"Infantino, Maria"' showing total 498 results
Start Over Author "Infantino, Maria"
498 results on '"Infantino, Maria"'

7. Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop

Author

Andrade, Luis E.C., Klotz, Werner, Herold, Manfred, Musset, Lucile, Damoiseaux, Jan, Infantino, Maria, Carballo, Orlando G., Choi, May, von Mühlen, Carlos A., Garcia-De La Torre, Ignacio, Satoh, Minoru, Francescantonio, Paulo L.C., Mimori, Tsuneyo, Conrad, Karsten, de Melo Cruvinel, Wilson, Chan, Edward K.L., and Fritzler, Marvin J.

Published
2024
Full Text
View/download PDF

9. Immunogenicity after two and three doses of mRNA vaccine in patients with cancer treated with exclusive radiotherapy

Author

Scoccianti, Silvia, Delli Paoli, Camilla, Infantino, Maria, Paoletti, Lisa, Caini, Saverio, Meacci, Fiammetta, Russo, Serenella, Esposito, Marco, Fondelli, Simona, Grilli Leonulli, Barbara, Grossi, Valentina, Barca, Raffaella, Alpi, Paolo, Furlan, Federica, Perna, Marco, Pino, Maria Simona, Martella, Francesca, Manfredi, Mariangela, Stefanacci, Marco, Bassetti, Andrea, Casprini, Patrizia, and Fioretto, Luisa

Published
2023
Full Text
View/download PDF

11. JAK inhibitors and autoimmune rheumatic diseases

Author

Benucci, Maurizio, Bernardini, Pamela, Coccia, Carmela, De Luca, Riccardo, Levani, Juela, Economou, Alessio, Damiani, Arianna, Russo, Edda, Amedei, Amedeo, Guiducci, Serena, Bartoloni, Elena, Manfredi, Mariangela, Grossi, Valentina, Infantino, Maria, and Perricone, Carlo

Published
2023
Full Text
View/download PDF

12. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations

Author

Fredi, Micaela, Cavazzana, Ilaria, Ceribelli, Angela, Cavagna, Lorenzo, Barsotti, Simone, Bartoloni, Elena, Benucci, Maurizio, De Stefano, Ludovico, Doria, Andrea, Emmi, Giacomo, Fabris, Martina, Fornaro, Marco, Furini, Federica, Giudizi, Maria Grazia, Govoni, Marcello, Ghirardello, Anna, Iaccarino, Luca, Iannone, Fiorenzo, Infantino, Maria, Isailovic, Natasa, Lazzaroni, Maria Grazia, Manfredi, Mariangela, Mathieu, Alessandro, Marasco, Emiliano, Migliorini, Paola, Montecucco, Carlomaurizio, Palterer, Boaz, Parronchi, Paola, Piga, Matteo, Pratesi, Federico, Riccieri, Valeria, Selmi, Carlo, Tampoia, Marilina, Tripoli, Alessandra, Zanframundo, Giovanni, Radice, Antonella, Gerli, Roberto, and Franceschini, Franco

Published
2022
Full Text
View/download PDF

15. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study

Author

Farroni, Chiara, Aiello, Alessandra, Picchianti-Diamanti, Andrea, Laganà, Bruno, Petruccioli, Elisa, Agrati, Chiara, Garbuglia, Anna Rosa, Meschi, Silvia, Lapa, Daniele, Cuzzi, Gilda, Petrone, Linda, Vanini, Valentina, Salmi, Andrea, Altera, Anna Maria Gerarda, Repele, Federica, Grassi, Germana, Bettini, Aurora, Vita, Serena, Mariano, Andrea, Damiani, Arianna, Infantino, Maria, Grossi, Valentina, Manfredi, Mariangela, Niccoli, Laura, Puro, Vincenzo, Rosa, Roberta Di, Salemi, Simonetta, Sesti, Giorgio, Scolieri, Palma, Bruzzese, Vincenzo, Benucci, Maurizio, Cantini, Fabrizio, Nicastri, Emanuele, and Goletti, Delia

Published
2022
Full Text
View/download PDF

17. Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience

Author

Infantino, Maria, Morena, Lorenza, Di Pietro, Massimo Antonio, Romanin, Benedetta, Cimolato, Barbara, Rocca, Beatrice Anna Luisa, Tunnera, Silvia, Modi, Giulia, Tilli, Marta, Grossi, Valentina, Lari, Barbara, Cerutti, Helena, Tesi, Giulia, Anrò, Valentina, Cartocci, Alessandra, Benucci, Maurizio, Veneziani, Francesca, Casprini, Patrizia, and Manfredi, Mariangela

Published
2022
Full Text
View/download PDF

18. Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases

Author

Bizzaro, Nicola, Villalta, Danilo, Bini, Vittorio, Migliorini, Paola, Franceschini, Franco, Piantoni, Silvia, Garrafa, Emirena, Riccieri, Valeria, Fioravanti, Antonella, Bellisai, Francesca, Tampoia, Marilina, Fornaro, Marco, Iannone, Florenzo, Ghirardello, Anna, Zen, Margherita, Palterer, Boaz, Parronchi, Paola, Infantino, Maria, Benucci, Maurizio, Rigon, Amelia, Arcarese, Luisa, Del Rosso, Stefania, Canti, Valentina, Bartoloni, Elena, and Gerli, Roberto

Published
2022
Full Text
View/download PDF

19. How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative

Author

von Mühlen, Carlos Alberto, Garcia-De La Torre, Ignacio, Infantino, Maria, Damoiseaux, Jan, Andrade, Luis E. C., Carballo, Orlando Gabriel, Conrad, Karsten, Francescantonio, Paulo Luiz Carvalho, Fritzler, Marvin J., Herold, Manfred, Klotz, Werner, de Melo Cruvinel, Wilson, Mimori, Tsuneyo, Satoh, Minoru, Musset, Lucile, and Chan, Edward K. L.

Published
2021
Full Text
View/download PDF

23. Diagnostic accuracy of anti-phospholipase A2 receptor (PLA2R) antibodies in idiopathic membranous nephropathy: an Italian experience

Author

Porcelli, Brunetta, Guarnieri, Andrea, Ferretti, Fabio, Garosi, Guido, Terzuoli, Lucia, Cinci, Francesca, Tabucchi, Antonella, Tampoia, Marilina, Abbracciavento, Letizia, Villani, Chiara, Deleonardi, Gaia, Grondona, Ana Gabriela, Mazzolini, Marcello, La Manna, Gaetano, Santostefano, Marisa, Infantino, Maria, Manfredi, Mariangela, Spatoliatore, Giuseppe, Rosati, Alberto, Somma, Chiara, and Bizzaro, Nicola

Published
2021
Full Text
View/download PDF

24. Advanced Atrioventricular Block in Athletes: Prevalence and Role of Anti-Ro/Sjögren Syndrome--Related Antigen A Antibodies.

Author

Lazzerini, Pietro Enea, Bertolozzi, Iacopo, Cartocci, Alessandra, Ginjupalli, Vamsi Krishna Murthy, Teneggi, Pietro Alberto, Pica, Davide, Merico, Giovanni, Bogazzi, Irene, Salvini, Viola, Accioli, Riccardo, Salvadori, Fabio, Marzotti, Tommaso, Cevenini, Gabriele, Capecchi, Matteo, Cantara, Silvia, Cantore, Anna, Infantino, Maria, Bisogno, Stefania, Finizola, Francesco, and D'ascenzi, Flavio

Published
2024
Full Text
View/download PDF

25. Do Ultrasound Lung Abnormalities Correlate to Biomarkers and Male Gender in Rheumatoid Arthritis Patients? A Monocentric Cross-Sectional Study.

Author

Bandinelli, Francesca, Benucci, Maurizio, Mallia, Ilenia, Mauro, Ilaria, Pecani, Nikita, Li Gobbi, Francesca, Manfredi, Mariangela, Guiducci, Serena, Lari, Barbara, Grossi, Valentina, Infantino, Maria, and Giannasi, Gianfranco

Subjects
LUNGS, RHEUMATOID arthritis, BIOMARKERS, SMOKING, RHEUMATOID factor, ULTRASONIC imaging
Abstract

Background: Lung ultrasound (LUS) is a tool of growing interest in Rheumatoid Arthritis (RA) oligo- symptomatic ILD to avoid. Objective: We aimed to evaluate (i) the prevalence of pleural (PLUS) and parenchymal (PAUS) abnormalities in LUS in the RA population and their possible correlation to biomarkers; (ii) the predictivity of gender, smoking habits, previous infections (past COVID-19 tuberculosis), and treatments; (iii) the differences in LUS between sexes. Methods: We collected the data of 155 (15 early and 140 late) RA patients with mild respiratory symptoms, evaluating PLUS and PAUS, in fourteen lung areas and also summing the scores (LUS-T). Results: Only 13/155 (8.4%) were completely negative; LUS correlated to age (all parameters p 0.0001), rheumatoid factor IgM (PLUS p 0.0006, PAUS p 0.02, LUS-T p 0.001) and ACPA (p 0.001, 0.006, 0.001, respectively), and PLUS also correlated to IL6 (p 0.02). The male gender was predictive of all LUS evaluations (p 0.001, 0.05, 0.001, respectively), which were higher than in women (p 0.001, 0.01, 0.001, respectively). Other potential risk factors were independent, except biological treatments, which showed a low predictivity to PLUS (p < 0.05). Conclusions: We can conclude that LUS is a useful technique in RA low respiratory symptoms and correlates with age, the most important RA biomarkers, and male sex. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain

Author

Infantino, Maria, primary, Foddai, Silvia, additional, Manfredi, Mariangela, additional, Benucci, Maurizio, additional, Radin, Massimo, additional, Cecchi, Irene, additional, Barinotti, Alice, additional, Aluf, Ofir, additional, Rubini, Elena, additional, Elnaz, Rahbari, additional, Menegatti, Elisa, additional, Roccatello, Dario, additional, and Sciascia, Savino, additional

Published
2023
Full Text
View/download PDF

30. Adopting the International Consensus on ANA Patterns (ICAP) classification for reporting: the experience of Italian clinical laboratories.

Author

Infantino, Maria, Bizzaro, Nicola, de Melo Cruvinel, Wilson, Chan, Edward K.L., and Andrade, Luis E.C.

Subjects
*ANTINUCLEAR factors, *RHEUMATISM, *PATHOLOGICAL laboratories, *AUTOIMMUNE diseases, *AUTOANTIBODIES, *IMMUNOFLUORESCENCE
Abstract

The indirect immunofluorescence assay on HEp-2 cells (HEp-2 IFA) is still considered the reference method to detect anti-nuclear antibodies (ANA) because of its high sensitivity and represents a relevant tool for the diagnosis of autoimmune rheumatic diseases. During the last decade, the International Consensus on ANA Patterns (ICAP) initiative promoted harmonization and understanding of HEp-2 IFA staining pattern nomenclature, as well as promoting their use in patient care by providing interpretation for HEp-2 IFA test results. In conjunction with a nationwide survey on the evolution of autoantibody diagnostics in autoimmune rheumatic diseases, we focused on the adherence of the Italian laboratories to the ICAP nomenclature analyzing its lights and shadows. The recent ICAP-oriented report, largely used today among Italian laboratories, also represents a further step in harmonizing and improving communication with the clinicians, adding value to laboratory findings and helping with critical clinical decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Rekomendacje EFLM, EASI oraz ICAP: Detekcja przeciwciał przeciwjądrowych Publikacja EFLM.

Author

Bonroy, Carolien, Vercammen, Martine, Fierz, Walter, Andrade, Luis E. C., Van Hoovels, Lieve, Infantino, Maria, Fritzler, Marvin J., Bogdanos, Dimitrios, Kozmar, Ana, Nespola, Benoit, Broeders, Sylvia, Patel, Dina, Herold, Manfred, Zheng, Bing, Chan, Eric Y. T., Uibo, Raivo, Haapala, Anna-Maija, Musset, Lucile, Sack, Ulrich, and Nagy, Gabor

Subjects
COMPUTER-aided diagnosis, ANTINUCLEAR factors, CLINICAL chemistry, EUROPEAN integration, CHEMICAL laboratories
Abstract

Copyright of Journal of Laboratory Diagnostics / Diagnostyka Laboratoryjna is the property of Index Copernicus International and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

32. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA- i Study).

Author

Benucci, Maurizio, Li Gobbi, Francesca, Damiani, Arianna, Russo, Edda, Guiducci, Serena, Manfredi, Mariangela, Lari, Barbara, Grossi, Valentina, and Infantino, Maria

Subjects
CALPROTECTIN, RHEUMATOID arthritis, MAJOR adverse cardiovascular events, PLASMINOGEN activators, HERPES zoster
Abstract

Background: Real-world evidence of the efficacy and adverse events of JAK inhibitor treatment (Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib) in rheumatoid arthritis is still limited. Methods: We studied 115 patients from the Rheumatology Unit of S. Giovanni di Dio Hospital affected by D2T-RA, according to the 2010 EULAR criteria. Out of the 115 patients, 17 had been treated with Baricitinib 8 mg/daily, 32 with Filgotinib 200 mg/daily, 21 with Tofacitinib 10 mg/daily, and 45 with Upadacitinib 15 mg/daily. We evaluated the clinical response after 3, 6, and 12 months of treatment and the follow-up from September 2022 to September 2023. All patients were evaluated according to the number of tender joints (NTJs), number of swollen joints (NSJs), visual analog scale (VAS), global assessment (GA), health assessment questionnaire (HAQ), Disease Activity Score (DAS28), and CDAI. Furthermore, laboratory parameters of efficacy and tolerability were evaluated. Results: All treatments demonstrated a statistically significant decrease in the DAS28 and CDAI scores, tender and swollen joint counts, VAS, HAQ, and patient global assessment (PGA) after 3, 6, and 12 months of treatment. All treatments showed similar behavior, and statistically significant decreases in circulating calprotectin, TNFα, and IL-6 were observed for all drugs after 12 months of treatment. In addition, soluble urokinase plasminogen activator receptor (suPAR) values showed significant differences at baseline and after 12 months of treatment for Filgotinib: 4.87 ± 4.53 vs. 3.61 ± 0.9 (0.009) and Upadacitinib: 6.64 ± 7.12 vs. 4.06 ± 3.61 (0.0003), while no statistically significant differences were found for Baricitinib: 3.4 ± 0.1 vs. 3.78 ± 0.1 and Tofacitinib: 3.95 ± 1.77 vs. 2.58 ± 0.1. The TC/HDL-C ratio (atherogenic index) showed significant differences when comparing Baricitinib vs. Filgotinib (0.0012), Filgotinib vs. Tofacitinib (0.0095), and Filgotinib vs. Upadacitinib (0.0001); furthermore, the LDL-C/HDL-C ratio in the Filgotinib group did not change (2.37 ± 0.45 vs. 2.35 ± 2.13 (NS)) after 12 months of treatment. Venous Thrombotic Events (VTEs) and major adverse cardiovascular events (MACEs) accounted for 1% of adverse events after treatment with Baricitinib. Herpes zoster reactivation accounted for 1% of adverse events after treatment with Filgotinib and Tofacitinib, while non-melanoma skin cancer (NMSC) accounted for 1% of adverse events after Upadacitinib treatment. Conclusions: Our real-world data from patients with RA show differences in some laboratory parameters and in the impact of lipid metabolism in JAK inhibitor treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Autoantibody status according to multiparametric assay accurately estimates connective tissue disease classification and identifies clinically relevant disease clusters

Author

Cafaro, Giacomo, primary, Bartoloni, Elena, additional, Baldini, Chiara, additional, Franceschini, Franco, additional, Riccieri, Valeria, additional, Fioravanti, Antonella, additional, Fornaro, Marco, additional, Ghirardello, Anna, additional, Palterer, Boaz, additional, Infantino, Maria, additional, Rigon, Amelia, additional, Del Rosso, Stefania, additional, Gerli, Roberto, additional, Villalta, Danilo, additional, and Bizzaro, Nicola, additional

Published
2023
Full Text
View/download PDF

37. Algorithmic Torts: A Prospective Comparative Overview

Author

Infantino, Maria and Wang, Weiwei

Subjects
Algorithms -- Laws, regulations and rules -- Remedies -- Social aspects, Tort liability -- Comparative analysis -- Laws, regulations and rules -- Research, Government regulation, Algorithm, Law
Abstract

In more or less noticeable ways, algorithms are pervading every sector of life. As algorithm-related activities multiply around us, it is reasonable to predict that so will accidents and, consequently, compensation claims framed as torts. Against this background, the paper investigates from a comparative perspective how legal systems in three regions of the world--the U.S., (continental) Europe, and China--could approach the rise of algorithmic torts. First, the paper sketches out the main features that might be associated with algorithm-related torts and the specific challenges that they might bring to current legal frameworks. It then presents the state-of-the-art of the legal debate about algorithmic liability in U.S., Europe, and China. Finally, the paper delves into the ways in which tort laws in these three regions might address injuries associated with algorithmic activities, reviewing in particular the criteria for grounding jurisdiction, the procedural devices applying to tort law claims, the liability regimes under which claims could be framed, the mechanisms for damage attribution and apportionment, and the type and amount of potential recoverable losses., I. INTRODUCTION 310 II. MAPPING THE FIELD 316 III. THE ENDLESS CODING OF POSSIBLE ACCIDENTS 320 IV. COMPARING SOLUTIONS 325 A. The U.S. 329 B. Europe 331 C. China 334 [...]

Published
2019

39. Anti-DFS70 antibodies detected by specific methods in patients with thrombosis or recurrent pregnancy loss: no evidence of an association

Author

Bizzaro, Nicola, Pesce, Giampaola, Trevisan, Maria Teresa, Marchiano, Manuela, Cinquanta, Luigi, Infantino, Maria, Paura, Giusy, Tampoia, Marilina, Alessio, Maria Grazia, Previtali, Giulia, Marchese, Magda, Zullo, Clelia, Villalta, Danilo, Brusca, Ignazio, Laneve, Mario, Castiglione, Caterina, Carbone, Teresa, Curcio, Carmela, Invernizzi, Laura, Montecucco, Fabrizio, Saverino, Daniele, Ferretti, Fabio, and Porcelli, Brunetta

Published
2020
Full Text
View/download PDF

41. Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

Author

Manfredi, Mariangela, primary, Van Hoovels, Lieve, additional, Benucci, Maurizio, additional, De Luca, Riccardo, additional, Coccia, Carmela, additional, Bernardini, Pamela, additional, Russo, Edda, additional, Amedei, Amedeo, additional, Guiducci, Serena, additional, Grossi, Valentina, additional, Bossuyt, Xavier, additional, Perricone, Carlo, additional, and Infantino, Maria, additional

Published
2023
Full Text
View/download PDF

43. Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP

Author

Bonroy, Carolien, primary, Vercammen, Martine, additional, Fierz, Walter, additional, Andrade, Luis E.C., additional, Van Hoovels, Lieve, additional, Infantino, Maria, additional, Fritzler, Marvin J., additional, Bogdanos, Dimitrios, additional, Kozmar, Ana, additional, Nespola, Benoit, additional, Broeders, Sylvia, additional, Patel, Dina, additional, Herold, Manfred, additional, Zheng, Bing, additional, Chan, Eric Y.T., additional, Uibo, Raivo, additional, Haapala, Anna-Maija, additional, Musset, Lucile, additional, Sack, Ulrich, additional, Nagy, Gabor, additional, Sundic, Tatjana, additional, Fischer, Katarzyna, additional, Rego de Sousa, Maria-José, additional, Vargas, Maria Luisa, additional, Eriksson, Catharina, additional, Heijnen, Ingmar, additional, García-De La Torre, Ignacio, additional, Carballo, Orlando Gabriel, additional, Satoh, Minoru, additional, Kim, Kyeong-Hee, additional, Chan, Edward K.L., additional, Damoiseaux, Jan, additional, Lopez-Hoyos, Marcos, additional, and Bossuyt, Xavier, additional

Published
2023
Full Text
View/download PDF

45. Detection of antinuclear antibodies : recommendations from EFLM, EASI and ICAP

Author

Bonroy, Carolien, Vercammen, Martine, Fierz, Walter, Andrade, Luis E.C., Van Hoovels, Lieve, Infantino, Maria, Fritzler, Marvin J., Bogdanos, Dimitrios, Kozmar, Ana, Nespola, Benoit, Broeders, Sylvia, Patel, Dina, Herold, Manfred, Zheng, Bing, Chan, Eric Y.T., Uibo, Raivo, Haapala, Anna-Maija, Musset, Lucile, Sack, Ulrich, Nagy, Gabor, Sundic, Tatjana, Fischer, Katarzyna, Rego De Sousa, Maria-José, Vargas, Maria Luisa, Eriksson, Catharina, Heijnen, Ingmar, García-De La Torre, Ignacio, Carballo, Orlando Gabriel, Satoh, Minoru, Kim, Kyeong-Hee, Chan, Edward K.L., Damoiseaux, Jan, Lopez-Hoyos, Marcos, Bossuyt, Xavier, Bonroy, Carolien, Vercammen, Martine, Fierz, Walter, Andrade, Luis E.C., Van Hoovels, Lieve, Infantino, Maria, Fritzler, Marvin J., Bogdanos, Dimitrios, Kozmar, Ana, Nespola, Benoit, Broeders, Sylvia, Patel, Dina, Herold, Manfred, Zheng, Bing, Chan, Eric Y.T., Uibo, Raivo, Haapala, Anna-Maija, Musset, Lucile, Sack, Ulrich, Nagy, Gabor, Sundic, Tatjana, Fischer, Katarzyna, Rego De Sousa, Maria-José, Vargas, Maria Luisa, Eriksson, Catharina, Heijnen, Ingmar, García-De La Torre, Ignacio, Carballo, Orlando Gabriel, Satoh, Minoru, Kim, Kyeong-Hee, Chan, Edward K.L., Damoiseaux, Jan, Lopez-Hoyos, Marcos, and Bossuyt, Xavier

Abstract

Objectives: Antinuclear antibodies (ANA) are important for the diagnosis of various autoimmune diseases. ANA are usually detected by indirect immunofluorescence assay (IFA) using HEp-2 cells (HEp-2 IFA). There are many variables influencing HEp-2 IFA results, such as subjective visual reading, serum screening dilution, substrate manufacturing, microscope components and conjugate. Newer developments on ANA testing that offer novel features adopted by some clinical laboratories include automated computer-assisted diagnosis (CAD) systems and solid phase assays (SPA). Methods: A group of experts reviewed current literature and established recommendations on methodological aspects of ANA testing. This process was supported by a two round Delphi exercise. International expert groups that participated in this initiative included (i) the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group “Autoimmunity Testing”; (ii) the European Autoimmune Standardization Initiative (EASI); and (iii) the International Consensus on ANA Patterns (ICAP). Results: In total, 35 recommendations/statements related to (i) ANA testing and reporting by HEp-2 IFA; (ii) HEp-2 IFA methodological aspects including substrate/conjugate selection and the application of CAD systems; (iii) quality assurance; (iv) HEp-2 IFA validation/verification approaches and (v) SPA were formulated. Globally, 95% of all submitted scores in the final Delphi round were above 6 (moderately agree, agree or strongly agree) and 85% above 7 (agree and strongly agree), indicating strong international support for the proposed recommendations. Conclusions: These recommendations are an important step to achieve high quality ANA testing.

Published
2023
Full Text
View/download PDF

48. Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2023
Full Text
View/download PDF

50. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Russo, Edda, additional, Guiducci, Serena, additional, Li Gobbi, Francesca, additional, Fusi, Paola, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Manfredi, Mariangela, additional, and Infantino, Maria, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results